U-101

U-101 is a small molecule antiviral drug candidate developed by the University of Minnesota's Center for Drug Design for the treatment of COVID-19. It acts as a potent inhibitor of the SARS-CoV-2 main protease (Mpro, also known as 3CLpro), an enzyme essential for viral replication. Unlike some other Mpro inhibitors, U-101 is designed to be orally bioavailable and has shown significant efficacy in preclinical models, including activity against various SARS-CoV-2 variants. The compound's structure features a triazinane-2,4-dione core, which contributes to its stability and inhibitory profile.

Other names

(6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazinane-2,4-dione